Self-reported Cannabidiol (CBD) Use for Conditions With Proven Therapies
- PMID: 33057645
- PMCID: PMC7563067
- DOI: 10.1001/jamanetworkopen.2020.20977
Self-reported Cannabidiol (CBD) Use for Conditions With Proven Therapies
Abstract
Importance: Use of cannabidiol (CBD) has markedly increased in the past 5 years, concurrent with marketing claims that over-the-counter CBD can be used to treat almost any health condition. However, the reasons why individuals use CBD remain unclear.
Objective: To assess whether individuals are using CBD for diagnosable conditions that have evidence-based therapies.
Design, setting, and participants: This case series assessed claimed treatment applications reported by CBD users in public testimonials shared on the Reddit forum r/CBD. The r/CBD forum was selected because it includes a large, naturally occurring sample of 104 917 registered individuals who publicly discuss their experiences using CBD. All r/CBD posts were obtained from January 1, 2014, through August 31, 2019. A random sample of posts was drawn (n = 3000) and filtered to include posts in which self-identified CBD users testified why they take CBD (n = 376).
Exposures: Self-reported use of CBD for medicinal purposes.
Main outcomes and measures: Cannabidiol testimonials were divided into 11 subcategories corresponding with the condition's medical subspecialty and 2 subcategories corresponding with wellness benefits. Posts were allowed to receive more than 1 label.
Results: Of the 376 posts labeled as testimonials, 90.0% (95% CI, 86.8%-92.8%) of testimonials claimed that CBD treated the individual's diagnosable conditions. Psychiatric conditions (eg, autism or depression) were the most frequently cited subcategory, mentioned in 63.9% (95% CI, 59.0%-69.1%) of testimonials, followed by orthopedic (26.4%; 95% CI, 21.8%-31.1%), sleep (14.6%; 95% CI, 11.3%-18.5%), and neurological (6.9%; 95% CI, 4.4%-9.6%) conditions. Testimonials also claimed that CBD treated gastroenterological conditions (3.9%; 95% CI, 1.9%-6.1%), as well as addiction, cardiological, dermatological, ophthalmological, oral health, and sexual health conditions (<2.0% each). By contrast, just 29.5% (95% CI, 24.8%-34.2%) of testimonies claimed any wellness benefit, with most citing mental wellness (eg, "quieting my mind") (29.5% [95% CI, 24.2%-34.4%]); 1.4% (95% CI, 0.3%-2.8%) claimed a physical wellness benefit (eg, "exercise performance").
Conclusions and relevance: The findings of this case series suggest a need for regulation of factors associated with CBD being used to treat diagnosable conditions, engagement of health care professionals with patients on their potential CBD use, and implementation of public health campaigns that encourage the public to seek treatment advice from health care professionals regarding evidence-based therapies.
Conflict of interest statement
Figures
Comment in
-
The Need for Evidence Regarding Cannabidiol.JAMA Netw Open. 2020 Oct 1;3(10):e2021067. doi: 10.1001/jamanetworkopen.2020.21067. JAMA Netw Open. 2020. PMID: 33057640 No abstract available.
Similar articles
-
Cannabidiol: pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders.Epilepsia. 2014 Jun;55(6):791-802. doi: 10.1111/epi.12631. Epub 2014 May 22. Epilepsia. 2014. PMID: 24854329 Free PMC article. Review.
-
Cannabidiol or CBD Oil: Help, Hope, and Hype for Psychiatric and Neurologic Conditions.J Am Psychiatr Nurses Assoc. 2020 Sep/Oct;26(5):447-457. doi: 10.1177/1078390320929410. Epub 2020 Jun 6. J Am Psychiatr Nurses Assoc. 2020. PMID: 32508204
-
Use and perceptions of Cannabidiol among individuals in treatment for opioid use disorder.Harm Reduct J. 2024 Jul 17;21(1):135. doi: 10.1186/s12954-024-01051-5. Harm Reduct J. 2024. PMID: 39020418 Free PMC article.
-
Comparison of the Users' Attitudes Toward Cannabidiol on Social Media Platforms: Topic Modeling Study.JMIR Public Health Surveill. 2023 Jan 11;9:e34132. doi: 10.2196/34132. JMIR Public Health Surveill. 2023. PMID: 36630175 Free PMC article.
-
Cannabidiol (CBD) use in psychiatric disorders: A systematic review.Neurotoxicology. 2019 Sep;74:282-298. doi: 10.1016/j.neuro.2019.08.002. Epub 2019 Aug 11. Neurotoxicology. 2019. PMID: 31412258 Review.
Cited by
-
Pharmacovigilance in the Age of Legalized Cannabis: Using Social Media to Monitor Drug-Drug Interactions Between Immunosuppressants and Cannabis-Derived Products.Drug Saf. 2024 Sep 18. doi: 10.1007/s40264-024-01481-x. Online ahead of print. Drug Saf. 2024. PMID: 39292423
-
The Reddit cannabis subjective highness rating scale: Applying computational social science to explore psychological and environmental correlates of naturalistic cannabis use.PLoS One. 2024 Jun 25;19(6):e0300290. doi: 10.1371/journal.pone.0300290. eCollection 2024. PLoS One. 2024. PMID: 38917066 Free PMC article.
-
Consumer perception, knowledge, and uses of cannabidiol.Ment Health Clin. 2023 Oct 2;13(5):217-224. doi: 10.9740/mhc.2023.10.217. eCollection 2023 Oct. Ment Health Clin. 2023. PMID: 38131055 Free PMC article.
-
Long-Term, Self-Dosing CBD Users: Indications, Dosage, and Self-Perceptions on General Health/Symptoms and Drug Use.Med Cannabis Cannabinoids. 2023 Aug 16;6(1):77-88. doi: 10.1159/000531666. eCollection 2023 Jan-Dec. Med Cannabis Cannabinoids. 2023. PMID: 37900894 Free PMC article.
-
The therapeutic potential of purified cannabidiol.J Cannabis Res. 2023 Jun 13;5(1):21. doi: 10.1186/s42238-023-00186-9. J Cannabis Res. 2023. PMID: 37312194 Free PMC article. Review.
References
-
- US Food and Drug Administration Office of the Commissioner. FDA regulation of cannabis and cannabis-derived products, including cannabidiol (CBD). Published January 15, 2020. Accessed February 4, 2020. https://www.fda.gov/news-events/public-health-focus/fda-regulation-canna...
-
- National Center for Complementary and Integrative Health NIH to investigate minor cannabinoids and terpenes for potential pain-relieving properties. Published September 19, 2019. Accessed August 4, 2020. https://www.nih.gov/news-events/news-releases/nih-investigate-minor-cann...
-
- US Food and Drug Administration Office of the Commissioner. What you need to know (and what we’re working to find out) about products containing cannabis or cannabis-derived compounds, including CBD. Published March 3, 2020. Accessed August 4, 2020. https://www.fda.gov/consumers/consumer-updates/what-you-need-know-and-wh...
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
